ATTN: Gerry Pyle
An Adobe PDF VERSION OF THE APPLICATION GUIDELINES CAN BE OPENED OR DOWNLOADED BY Clicking Here.
APPLICATION DEADLINE: February 28, 2013
Grants can be submitted in PDF or similar digital format. See Application Requirements.
Signature pages can be scanned, mailed separately, or a digital signature sent.
Suggested research reviewers must be submitted using the provided spreadsheet.
Seed money grants awarded by Ohio Cancer Research Associates are made to support research activities broadly related to cancer and leukemia. The organization seeks to fund research that will lead to continued support at the national level.
Grants are made by the Board of Trustees of Ohio Cancer Research Associates taking into account studies and recommendations of the Scientific Review Committee. Grants are available to investigators in either nonprofit or for-profit institutions, offices or clinics within the State of Ohio. However, grants to investigators working for profit-making organizations may not include funds for capital equipment. Grants are made with the stipulation of their use by a particular individual or group who are known as the principal investigator in support of a specific program of research under his/her/their direction.
Full professors or their equivalent are not eligible. Only tenure track, junior faculty or equivalent scientific staffs are generally considered as appropriate. Postdoctoral fellows, research associates, research assistants, and graduate students are ineligible to apply as P.I.’s, but they may be included as support staff.
The P.I. must show evidence of independence. Applicants must be within six years of their first independent research or faculty appointment. Well established investigators should not submit projects related to their current area of research.
Investigators previously funded by Ohio Cancer Research Associates must provide justification that this application is significantly different from the previously funded project. Information regarding the results of the previously funded proposal and the P.I.’s success in obtaining further national funding must also be provided.
Grants awarded by Ohio Cancer Research Associates are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.
All studies carried out as part of the proposed project must meet standards of informed consent for human subjects and/or proper care for animal subjects. Institutional approval of all research protocols involving human subjects or animal subjects must accompany the grant application.
In accordance with the needs of the research project, the funds granted may cover salaries for technical assistants, provisions for retirement benefits and social security for such assistants; cost of expendable supplies and experimental animals; special equipment when specifically justified for the execution of the project and other necessary costs. The grant budget should not include items for travel. Maximum awards will be up to $30,000 per year including indirect costs for a maximum of up to $60,000 for two years.
A justification for budgetary expenditure is required. The Scientific Review Committee of the Ohio Cancer Research Associates will review proposed budgets to ensure that the greatest number of projects can be realized with the overall funds available. Further, the Committee should be informed of contemplated major changes in the budget. Re-budgeting to travel is not permitted.
Research funds may not be used for building or plant construction, and are not to be used to replace any obligations currently assumed by the institution or individual receiving the grant. Research funds may not be used to pay any physician for any type of patient care. A physician who is doing purely technical or laboratory work, for which he has been qualified by other than his professional medical education, may be paid as a technical assistant. Research funds may not be used for salary for the P.I.
Charges for supplies, personnel services, and equipment obtained or expended prior to the beginning date of the grant or subsequent to the closing date may not be charged. However, the cost of equipment ordered during the period of the grant may be charged against it even though the equipment is not actually received until after the end of the period. At the termination of the grant all unexpended funds are to be returned to Ohio Cancer Research Associates. Ohio Cancer Research Associates cannot assume responsibility for deficits created by overdrafts on grant funds.
Indirect costs of 10% of personnel and supplies will be paid to nonprofit institutions. No indirect costs will be paid on equipment to be purchased or patient care costs. No indirect costs will be paid to profit-making organizations.
The principal investigator is the senior investigator who assumes overall responsibility for the design and execution of the research project, and the preparation of both the progress and final reports.
Special equipment required for the project may be included in the budget if such equipment is not available in the institution where the project is located. Such equipment remains the property of Ohio Cancer Research Associates under the stewardship of the principal investigator until the project period and all renewals of the original grant period are concluded. The ownership of equipment proceeds to the sponsoring institution unless prior arrangements for the disposition of the equipment are made during the tenure of the grant.
For individuals awarded two year grants, a progress report covering the first eight months of the grant period is due in the Ohio Cancer Research Associates office sixty (60) days before the end of the first year. Compliance with timely submission of this report, demonstrated satisfactory progress and availability of funds will be considered prior to the awarding of the second year of funding. Please include a budget for the second year and a listing of all and pending grants with amount and specific aim.
A final progress report of work accomplished will be required, regardless of the duration of the grant. Grantees whose grants are being terminated (including those investigators who are leaving Ohio) should submit final reports within thirty (30) days after termination of the grant.
Additional funding received as a result of the seed money grant should be reported to Ohio Cancer Research Associates with the amount, source, and how the seed money grant helped in obtaining the additional funding.
Publications resulting from work carried out under an Ohio Cancer Research Associates grant must carry this statement: “This study has been supported (in part) by a grant from Ohio Cancer Research Associates, Inc.” Five reprints of publications are to be forwarded to the Ohio Cancer Research Associates office. Also, any newspaper, radio, television or other publicity received by the researcher in connection with the funded project must have appropriate credit given to Ohio Cancer Research Associates.
Researcher receiving funds may be asked to speak at Ohio Cancer Research Associates meetings and fundraising events.
1. All inventions made with the support, in whole or in part, of Ohio Cancer Research Associates funds shall be timely reported to Ohio Cancer Research Associates.
2. If the institution receiving or disbursing the Ohio Cancer Research Associates funds with which the invention was made has an established patent policy and procedure administering inventions, Ohio Cancer Research Associates will defer to that policy with the following restrictions:
a. Title to any invention shall not be permitted to reside with the inventor or any other individual without prior written approval of Ohio Cancer Research Associates upon advice of legal counsel.
b. No patent or patent application shall be abandoned without first notifying Ohio Cancer Research Associates and giving Ohio Cancer Research Associates the opportunity to continue the patent application at its own expense.
c. Unless there is an institution policy stating otherwise, the inventor(s) may share in the income derived from the invention provided that the inventor(s) will not be paid more that twenty-five percent (25%) of the gross royalty income without prior written approval of Ohio Cancer Research Associates.
d. Ohio Cancer Research Associates shall participate in the income derived from the invention to an extent to be determined by mutual agreement between the institution and Ohio Cancer Research Associates.
3. If the institution has no established patent policy and procedure for administering inventions, Ohio Cancer Research Associates shall have the right to determine the disposition of the invention rights. In such cases, Ohio Cancer Research Associates may:
a. Decide that no patent applications are to be filed.
b. Release the invention to the inventor or his designee.
c. If the invention is administered by a Research Corporation or other similar nonprofit organization, Ohio Cancer Research Associates may determine that a share of the income is to be paid to the inventor(s), but not to exceed twenty-five percent (25%) of the gross royalty income.
4. Notwithstanding any of the foregoing, if any invention is made with the joint support of Ohio Cancer Research Associates and any agency or department of the United States Government, Ohio Cancer Research Associates will defer to the patent policy of that agency or department upon receipt of a written statement by the appropriate agency of government notifying Ohio Cancer Research Associates of its position with respect to the invention in question.
5. If any invention is made with the joint support of Ohio Cancer Research Associates and some organization other than any agency or department of the United States Government, including but not limited to Ohio Cancer Research Associates, or that organization, the institution, the inventor(s) and Ohio Cancer Research Associates will confer to determine a mutually satisfactory disposition of the invention rights.
New Grants. In general, grants are made once a year for a period beginning July 1. Application may be submitted at any time, but must be received not later than February 28, 2013 for the grant period beginning July 1, 2013. Investigators will normally be notified concerning action on the applications by June 30, 2013. Renewal for 2nd year of grant is dependent on the progress report.
Renewal Requests. Renewal requests may be submitted according to the regulations for the new grants stated above. It is a general policy that grants will not be renewed for more than one year. In addition to the usual request form for grants, a detailed renewal justification must be submitted.
Change of Grant Period. Although each grant is made for use within a specific project period, an extension of the period without additional funds may be approved when requested and justified by the principal investigator. These requests should be submitted in writing to the Grants Committee thirty (30) days before the termination of the grant. Requests for extension of unexpended funds at no cost to Ohio Cancer Research Associates may be granted for a period up to six months. Requests for extension for longer than six months may be granted in rare circumstances after review by the Scientific Review Committee.
Specifics for the upcoming granting period are detailed below.
If the principal investigator leaves the institution before expiration of the grant, the grant is terminated and the unexpended balance is forfeited. If arrangements satisfactory to the Scientific Review Committee are completed in such instances, the balance of the grant can be transferred to a new institution in Ohio at which the research program is to be continued or a new principal investigator may be recommended, subject to approval by the Scientific Review Committee, to complete the project at the original institution.
In the event that an investigator applies to another granting agency for funds to support the same project, and both applications are granted, the investigator must select the award of his/her/their choice and decline the duplicate award.
Submit the application in PDF or similar digital format (7 MB size limit per e-mail) to email@example.com. Files larger than 7 MB can be submitted online at http://www.ohiocancer.org/grants/upload/submit.asp.
Applications should be received no later than February 28, 2013, for the grant period beginning July 1, 2013.
Suggested reviewers (see below) must be submitted separately.
Since the goal of Ohio Cancer Research Associates is to fund research that will lead to continued support at the national level, the standard NIH forms (Form 398) should be used, or a reasonable equivalent thereof. In either case, the application should contain the following information:
Name and degree of principal investigator
Mailing address, phone/fax numbers & e-mail address of principal investigator
Title of project
Citizenship and Visa status (may be included in biographical information)
Amount requested for first year (direct plus indirect costs)
Total amount requested
Name and address of applicant organization for sponsored research
Name, title, and signature of institutional official
Signature of principal investigator
Abstract of project and names, titles and proposed roles of scientific staff required for projects.
Table of contents.
Detailed first year budget, including personnel costs and fringe benefits, equipment, supplies and miscellaneous expenses. Please note that no funds for travel or renovations are permitted. Include a line for direct, indirect and total costs for the first year. Indirect costs cannot exceed 10%. (Indirect costs not paid to equipment or patient care.)
Budget for entire period requested (not to exceed two years), listed by category only, and justification of budget.
The following should be placed after the budget justification in the order indicated below:
1. Biographical sketch of principal investigator with Citizenship and Visa status if not on page 1, including publications (2 pages maximum).
2. Biographical sketches of co-investigators or senior scientific staff (2 pages each maximum)
3. Current and pending support of the principal investigator, listing title, agency, amount of award and inclusive dates. Indicate any overlapping or duplicate proposals.
4. Facilities available (1 page maximum)
5. Documentation of human subjects approval, including dates and protocol number. If no human subjects are to be used, a statement to that effect should be included.
6. Documentation of approval for the use of animals, including dates and protocol number. If none are to be used, a statement to that effect should be included.
7. Biohazards to be encountered in the course of the research, including recombinant DNA, and a statement concerning how risk will be minimized.
10 page maximum, exclusive of references.
No more than three documents may be submitted as Appendix material.
1. Specific aims. State the short and long term goals of the project.
2. Background and significance. Include a brief summary of work done by the principal investigator and others relevant to the proposed project. Indicate the significance of the project and its relevance to cancer/leukemia.
3. Experimental plan. Describe the methodology to be used to accomplish each of the specific aims. Describe the results that are to be expected and how they will be evaluated. Indicate the potential pitfalls of the approach, their significance to the overall success of the project, and alternative approaches that will be considered. Although explicit details of procedures are not required, enough information should be available to allow a knowledgeable reviewer to assess the validity of the methodology to be used.
4. Proposed schedule of experiments.
List the authors, title and complete citation of each reference cited. (4 pages maximum)
Include a paragraph justifying why seed money is required for the proposed project. It should indicate how the results obtained will allow the investigator to obtain peer-reviewed funding at the national level. A timetable for submission of such grant applications should be included. (Half page maximum)
Include a paragraph written in SIMPLE, 2nd GRADE LEVEL, NON-TECHNICAL LANGUAGE which describes the short and long-term goals of the project and how they relate to cancer or leukemia. If the project is funded, this description will be used for promotional or other public relations materials. (Half page maximum)
In the provided MS Excel spreadsheet (click here), list the name, complete address, and e-mail (if available) of at least six senior scientists, outside the state of Ohio, who could be contacted as external reviewers of your proposal.
Return the spreadsheet or document via e-mail separately from the application.
Remember to put your name and application title.
These individuals MUST have no previous or current formal affiliation with the investigator(s), but should have some expertise in the area of your grant proposal.
Contact information should be in all caps with NO punctuation.
The contact fields are:
SALUTATION (DR, MR, MS, PROF, etc.)
SUFFIX (PhD, MD, etc.)
ADDRESS LINE 1 – INCLUDE STREET NUMBER & STREET NAME, ROOM, SUITE OR FLOOR
ADDRESS LINE 2 – (OPTIONAL)
COUNTRY (IF NOT USA)
PHONE NUMBER (OPTIONAL)
FAX NUMBER (OPTIONAL)
This information is important to the review of the applicant’s proposal.